Cargando…

Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis

Current treatment recommendations for resectable pancreatic cancer support upfront resection and adjuvant therapy. Randomized controlled trials offering comparison with the emerging neoadjuvant approach are lacking. This review aims to compare both treatment strategies for resectable pancreatic canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bradley, Alison, Van Der Meer, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416273/ https://www.ncbi.nlm.nih.gov/pubmed/30867522 http://dx.doi.org/10.1038/s41598-019-40951-6

Ejemplares similares

Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis
por: Bradley, Alison, et al.
Publicado: (2019)

Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review
por: Ren, Xiaohan, et al.
Publicado: (2019)

Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Jung, Hye-Sol, et al.
Publicado: (2022)

Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
por: Versteijne, E., et al.
Publicado: (2018)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
por: Hu, Qiancheng, et al.
Publicado: (2019)

The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study
por: Su, Yung-Yeh, et al.
Publicado: (2023)

Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis
por: Lee, Yoon Suk, et al.
Publicado: (2019)

Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials
por: Ghanem, I., et al.
Publicado: (2022)

Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis
por: Ratnayake, Bathiya, et al.
Publicado: (2020)

A commentary on ‘The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study’
por: Chen, Yuan, et al.
Publicado: (2023)

Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer
por: Jeon, Hyun Jeong, et al.
Publicado: (2023)

Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis
por: Chen, Xing, et al.
Publicado: (2017)

The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer
por: Zwart, Eline S., et al.
Publicado: (2023)

A prognostic Bayesian network that makes personalized predictions of poor prognostic outcome post resection of pancreatic ductal adenocarcinoma
por: Bradley, Alison, et al.
Publicado: (2019)

Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis
por: Uson Junior, Pedro Luiz Serrano, et al.
Publicado: (2022)

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
por: Fossaert, Violette, et al.
Publicado: (2022)

Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I–III pancreatic ductal adenocarcinoma: a retrospective cohort study
por: Zou, Yiping, et al.
Publicado: (2023)

Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment
por: Fujii, Tsutomu, et al.
Publicado: (2015)

Neoadjuvant therapy or upfront surgery in advanced endometrial cancer: a systematic review protocol
por: McCarthy, Amy, et al.
Publicado: (2021)

An invited commentary on ‘Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study’
por: Coppola, Alessandro, et al.
Publicado: (2023)

Comparison of prognosis between neoadjuvant imatinib and upfront surgery for GIST: A systematic review and meta-analysis
por: Liu, Zhen, et al.
Publicado: (2022)

Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasing Perioperative Complications
por: Deig, Christopher Ryan, et al.
Publicado: (2022)

Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis
por: Ono, Kosuke, et al.
Publicado: (2021)

Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies
por: Pecorelli, Nicolò, et al.
Publicado: (2022)

Neoadjuvant chemotherapy followed by surgery versus upfront surgery in non-metastatic non-small cell lung cancer: systematic review and meta-analysis of randomized controlled trials
por: Zhang, Xiao-Nan, et al.
Publicado: (2017)

Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysis
por: Yang, Zijiao, et al.
Publicado: (2023)

Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis
por: Pan, Long, et al.
Publicado: (2019)

Preoperative Endoscopic Ultrasound Fine Needle Aspiration Versus Upfront Surgery in Resectable Pancreatic Cancer: A Systematic Review and Meta-analysis of Clinical Outcomes Including Survival and Risk of Tumor Recurrence
por: Alghamdi, Adel, et al.
Publicado: (2021)

Comparison between upfront surgery and neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A systematic review
por: Fiflis, Stylianos, et al.
Publicado: (2023)

Early Recurrence after Upfront Surgery for Pancreatic Ductal Adenocarcinoma
por: Nappo, Gennaro, et al.
Publicado: (2023)

A systematic review of methodological quality of model development studies predicting prognostic outcome for resectable pancreatic cancer
por: Bradley, Alison, et al.
Publicado: (2019)

Neoadjuvant chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Meta-analysis and trial sequential analysis of randomized controlled trials
por: Hajibandeh, Shahab, et al.
Publicado: (2023)

Neoadjuvant therapy for resectable pancreatic cancer
por: Rahman, Sheikh Hasibur, et al.
Publicado: (2017)

Neoadjuvant therapy for resectable pancreatic cancers
por: Inoue, Yosuke, et al.
Publicado: (2022)

Prognostic Impact of Tumor-Infiltrating Lymphocytes and Neutrophils on Survival of Patients with Upfront Resection of Pancreatic Cancer
por: Miksch, Rainer C., et al.
Publicado: (2019)

Time from first seen in specialist care to surgery does not influence survival outcome in patients with upfront resected pancreatic adenocarcinoma
por: Brugel, M., et al.
Publicado: (2021)

Upfront Surgery versus Neoadjuvant Perioperative Chemotherapy for Resectable Colorectal Liver Metastases: A Machine-Learning Decision Tree to Identify the Best Potential Candidates under a Parenchyma-Sparing Policy
por: Famularo, Simone, et al.
Publicado: (2023)

Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
por: Gillen, Sonja, et al.
Publicado: (2010)

Postoperative morbidity and mortality after neoadjuvant chemotherapy versus upfront surgery for locally advanced gastric cancer: a propensity score matching analysis
por: Wu, Liucheng, et al.
Publicado: (2019)

Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Cloyd, Jordan M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_851etbroop5sjkrq7cae5t40q7